«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 14

Page:

2652-2656

Research Field:

Publishing date:

Info

Title:

Pathogenesis and therapeutic progress of breast cancer with receptor from "positive to negative"

Author(s):

HAN Ying¹; DI Lijun²

1.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department of Daycare Unit,Peking University Cancer Hospital & Institute,Beijing 100142,China£»2.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department of Breast Cancer Oncology,Peking University Cancer Hospital & Institute,Beijing 100142,China.

Keywords:

breast cancer; estrogen receptor; progesterone receptor; human epidermal growth factor receptor-2; from positive to negative; antibody-drug conjugates (ADC)

PACS:

R737.9

DOI:

10.3969/j.issn.1672-4992.2024.14.029

Abstract:

Breast cancer's high degree of heterogeneity presents a challenge for precision therapy.Molecular subtypes differing from expression of estrogen receptor (ER),progesterone receptor (PR) and human epidermal growth factor receptor-2(HER2) are essential for the proper diagnosis and therapy of breast cancer.For patients with recurrent or metastatic breast cancer,previous treatments have mainly been based on the receptor status of the primary lesion.Some studies have shown that the receptor expression of recurrence/metastasis is different from that of the primary lesion,which may be related to tumor heterogeneity and post-treatment clonal selection.Compared to the conversion of receptors from "negative to positive",the rate of receptor conversion from "positive to negative" is higher,and the loss of receptor expression may result in resistance to original therapy and worse prognosis for patients.Re-evaluation of the receptor status of breast cancer recurrence/metastasis has significant clinical significance for adjusting treatment strategies and judging prognosis,but whether clinical decision-making can be guided based on receptor changes is still controversial in clinical research or practice.With the emergence of various new anti-tumor drugs,such as targeted therapies,immune therapies,and antibody-drug conjugates (ADCs),optimizing treatment decisions and maximized benefits for "positive to negative" breast cancer patients have become significant unmet needs in clinical practice.The purpose of this article is to explore the molecular mechanism,prognostic factors and current treatment status of breast cancer with ¡°positive to negative ¡±,in order to provide theoretical support and practical guidance for the treatment of such patients.

References:

£Û1£ÝFERLAY J,ERVIK M,LAM F,et al.Global cancer observatory: Cancer today£ÛDB/OL£Ý.Lyon,France:International Agency for Research on Cancer£Û2024-05-20£Ý.https://gco.iarc.who.int/today.
£Û2£ÝMCANENA PF,MCGUIRE A,RAMLI A,et al.Breast cancer subtype discordance:impact on post-recurrence survival and potential treatment options £ÛJ£Ý.BMC Cancer,2018,18(1):203.
£Û3£ÝYI ZB,YU P,ZHANG S,et al.Profile and outcome of receptor conversion in breast cancer metastases:a nation-wide multicenter epidemiological study £ÛJ£Ý.Int J Cancer,2021,148(3):692-701.
£Û4£ÝAMIR E,CLEMONS M.Should a biopsy be recommended to confirm metastatic disease in women with breast cancer£ÛJ£Ý.Lancet Oncol,2009,10(10):933-935.
£Û5£ÝHENRY NL,SOMERFIELD MR,DAYAO Z,et al.Biomarkers for systemic therapy in metastatic breast cancer:ASCO guideline update £ÛJ£Ý.J Clin Oncol,2022,40(27):3205-3221.
£Û6£ÝDUFFY MJ,HARBECK N,NAP M,et al.Clinical use of biomarkers in breast cancer:Updated guidelines from the European Group on Tumor Markers (EGTM) £ÛJ£Ý.European Journal of Cancer,2017,75:284-298.
£Û7£ÝUNTCH M,W¦aRSTLEIN R,MARSCHNER N,et al.4th International Consensus Conference on Advanced Breast Cancer (ABC4),Lisbon,November 4,2017£ÛJ£Ý.Geburtshilfe Und Frauenheilkunde,2018,78(05):469-480.
£Û8£ÝÖйúÁÙ´²Ö×Áöѧ»áÖ¸ÄϹ¤×÷ίԱ»á.ÖйúÁÙ´²Ö×Áöѧ»á(CSCO)ÈéÏÙ°©ÕïÁÆÖ¸ÄÏ2023£ÛM£Ý.±±¾©:ÈËÃñÎÀÉú³ö°æÉç,2023:16-17. Chinese Society of Clinical Oncology Guidelines Working Committee.Chinese Society of Clinical Oncology (CSCO) breast cancer diagnosis and treatment guidelines 2023£ÛM£Ý.Beijing:People's Health Publishing House,2023:16-17.
£Û9£ÝSCHRIJVER WAME,SUIJKERBUIJK KPM,VAN GILS CH,et al.Receptor conversion in distant breast cancer metastases:A systematic review and Meta-analysis £ÛJ£Ý.Journal of the National Cancer Institute,2018,110(6):568-580.
£Û10£ÝCARLINO F,DIANA A,TERMINIELLO M,et al.302P Clinical implication of tissue re-biopsy in metastatic breast cancer (MBC) patients:A single centre retrospective analysis £ÛJ£Ý.Annals of Oncology,2021,32:S495-S496.
£Û11£ÝROQUE K,OTOYA I,VALDIVIESO N,et al.Discordance between hormone receptors and Her2 status in breast cancer patients relapse £ÛC£Ý.2023 SABCS PO5-06-05.
£Û12£ÝYEUNG C,HILTON J,CLEMONS M,et al.Estrogen,progesterone,and HER2/neu receptor discordance between primary and metastatic breast tumours-a review £ÛJ£Ý.Cancer and Metastasis Reviews,2016,35(3):427-437.
£Û13£ÝRAM¦VN Y CAJAL S,SES¦I M,CAPDEVILA C,et al.Clinical implications of intratumor heterogeneity:challenges and opportunities £ÛJ£Ý.Journal of Molecular Medicine,2020,98(2):161-177.
£Û14£ÝAURILIO G,DISALVATORE D,PRUNERI G,et al.A meta-analysis of oestrogen receptor,progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases £ÛJ£Ý.European Journal of Cancer,2014,50(2):277-289.
£Û15£ÝHU Z,LI Z,MA Z,et al.Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases £ÛJ£Ý.Nature Genetics,2020,52(7):701-708.
£Û16£ÝYI ZB,YU P,ZHANG S,et al.Profile and outcome of receptor conversion in breast cancer metastases:a nation-wide multicenter epidemiological study£ÛJ£Ý.International Journal of Cancer,2021,148(3):692-701.
£Û17£ÝZHAO W,SUN L,DONG G,et al.Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer £ÛJ£Ý.Therapeutic Advances in Medical Oncology,2021,13£ºunknown.
£Û18£ÝCHEN YF,XU YY,SHAO ZM,et al.Resistance to antibody-drug conjugates in breast cancer:mechanisms and solutions£ÛJ£Ý.Cancer Commun (Lond),2023,43(3):297-337.
£Û19£ÝSPROUFFSKE K,KERR G,LI C,et al.Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models £ÛJ£Ý.Computational and Structural Biotechnology Journal,2020,18:323-331.
£Û20£ÝGUIDI L,PELLIZZARI G,TARANTINO P,et al.Resistance to antibody-drug conjugates targeting HER2 in breast cancer:Molecular landscape and future challenges£ÛJ£Ý.Cancers (Basel),2023,15(4):1130.
£Û21£ÝALLRED DC.Commentary:Hormone receptor testing in breast cancer:A distress signal from Canada £ÛJ£Ý.The Oncologist,2008,13(11):1134-1136.
£Û22£ÝRAHEEM F,KARIKALAN SA,BATALINI F,et al.Metastatic ER+ breast cancer:mechanisms of resistance and future therapeutic approaches£ÛJ£Ý.Int J Mol Sci,2023,24(22):16198.
£Û23£ÝBALDUZZI A,BAGNARDI V,ROTMENSZ N,et al.Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression £ÛJ£Ý.Clinical Breast Cancer,2014,14(4):258-264.
£Û24£ÝALFAKEEH A,BREZDEN-MASLEY C.Overcoming endocrine resistance in hormone receptor-positive breast cancer £ÛJ£Ý.Current Oncology,2018,25(11):18-27.
£Û25£ÝLINDSTR¦ZM LS,KARLSSON E,WILKING UM,et al.Clinically used breast cancer markers such as estrogen receptor,progesterone receptor,and human epidermal growth factor receptor 2 are unstable throughout tumor progression £ÛJ£Ý.Journal of Clinical Oncology,2012,30(21):2601-2608.
£Û26£ÝLU Y,TONG Y,CHEN X,et al.Association of biomarker discrepancy and treatment decision,disease outcome in recurrent/metastatic breast cancer patients £ÛJ£Ý.Frontiers in Oncology,2021,11:638619.
£Û27£ÝMENG X,SONG S,JIANG ZF,et al.Receptor conversion in metastatic breast cancer:a prognosticator of survival £ÛJ£Ý.Oncotarget,2016,7(44):71887-71903.
£Û28£ÝWALTER V,FISCHER C,DEUTSCH TM,et al.Estrogen,progesterone,and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer £ÛJ£Ý.Breast Cancer Research and Treatment,2020,183(1):137-144.
£Û29£ÝSHIINO S,BALL G,SYED BM,et al.Prognostic significance of receptor expression discordance between primary and recurrent breast cancers:a meta-analysis £ÛJ£Ý.Breast Cancer Res Treat,2022,191(1):1-14.
£Û30£ÝLIN NU,THOMSSEN C,CARDOSO F,et al.International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force:Surveillance,staging,and evaluation of patients with early-stage and metastatic breast cancer £ÛJ£Ý.The Breast,2013,22(3):203-210.
£Û31£ÝWAKS AG,WINER EP.Breast cancer treatment £ÛJ£Ý.Jama,2019,321(3):288-300.
£Û32£ÝDUDEK AZ,LIU LC,FISCHER JH,et al.Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy£ÛJ£Ý.Breast Cancer Res Treat£¬2020£¬183(3):617-627.
£Û33£ÝWANDER SA,JURIC D,SUPKO JG,et al.Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor,ipatasertib,in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC)(TAKTIC)£ÛJ£Ý.Journal of Clinical Oncology,2020,38(15_suppl):1066.
£Û34£ÝCHANG HJ,HAN SW,OH DY,et al.Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab £ÛJ£Ý.Japanese Journal of Clinical Oncology,2011,41(5):593-599.
£Û35£ÝZHANG G,REN C,LI C,et al.Distinct clinical and somatic mutational features of breast tumors with high-,low-,or non-expressing human epidermal growth factor receptor 2 status £ÛJ£Ý.BMC Medicine,2022,20(1):142.
£Û36£ÝVAN RAEMDONCK E,FLORIS G,BERTELOOT P,et al.Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer £ÛJ£Ý.Breast Cancer Res Treat,2021,185(1):183-194.
£Û37£ÝANDERSON S,BARTOW BB,SIEGAL GP,et al.The dynamics of HER2-low expression during breast cancer progression £ÛJ£Ý.Breast Cancer Research and Treatment,2023,201(3):437-446.
£Û38£ÝBON G,PIZZUTI L,LAQUINTANA V,et al.Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade:the SePHER study £ÛJ£Ý.Journal of Experimental & Clinical Cancer Research,2020,39(1):279.
£Û39£ÝGENNARI A,ANDR¦I F,BARRIOS CH,et al.ESMO Clinical Practice Guideline for the diagnosis,staging and treatment of patients with metastatic breast cancer £ÛJ£Ý.Annals of Oncology,2021,32(12):1475-1495.
£Û40£ÝRINNERTHALER G,GAMPENRIEDER SP,GREIL R.HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer£ÛJ£Ý.Int J Mol Sci£¬2019£¬20(5):1115.
£Û41£ÝYAO L,CHEN J,MA W.Decoding TROP2 in breast cancer:significance,clinical implications,and therapeutic advancements£ÛJ£Ý.Front Oncol,2023,13:1292211.
£Û42£ÝUNTCH M,FASCHING PA,HAIDINGER R,et al.Advanced breast cancer £ÛJ£Ý.Geburtshilfe Und Frauenheilkunde,2022,82(10):1044-1054.
£Û43£ÝCRISCITIELLO C,ANDRE F,THOMPSON AM,et al.Biopsy confirmation of metastatic sites in breast cancer patients:clinical impact and future perspectives £ÛJ£Ý.Breast Cancer Res,2014,16(2):205.
£Û44£ÝLIEDTKE C,BROGLIO K,MOULDER S,et al.Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer £ÛJ£Ý.Annals of Oncology,2009,20(12):1953-1958.
£Û45£ÝMODI S,JACOT W,YAMASHITA T,et al.Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer £ÛJ£Ý.New England Journal of Medicine,2022,387(1):9-20.
£Û46£ÝD¦PAZ-RODR¦PGUEZ E,GANDULLO-S¦BNCHEZ L,OCA¦rA A,et al.Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs £ÛJ£Ý.Cancers,2021,14(1):154.
£Û47£ÝGOLDENBERG DM,STEIN R,SHARKEY RM.The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target £ÛJ£Ý.Oncotarget,2018,9(48):28989-29006.
£Û48£ÝGOLDENBERG DM,CARDILLO TM,GOVINDAN SV,et al.Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132),an antibody-drug conjugate (ADC) £ÛJ£Ý.Oncotarget,2015,6(26):22496-22512.
£Û49£ÝBARDIA A,HURVITZ SA,TOLANEY SM,et al.Sacituzumab govitecan in metastatic triple-negative breast cancer £ÛJ£Ý.New England Journal of Medicine,2021,384(16):1529-1541.
£Û50£ÝO' SHAUGHNESSY J,BRUFSKY A,RUGO HS,et al.Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer £ÛJ£Ý.Breast Cancer Research and Treatment,2022,195(2):127-139.
£Û51£ÝBARDIA A,TOLANEY SM,PUNIE K,et al.Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer £ÛJ£Ý.Annals of Oncology,2021,32(9):1148-1156.
£Û52£ÝRUGO HS,BARDIA A,MARM¦I F,et al.LBA76 overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)£ÛJ£Ý.Annals of Oncology,2023,41(16):1003.

Memo

Memo:

-

Common functions

Last Update: 1900-01-01